BeOne Medicines (ONC) Change in Receivables (2017 - 2026)

BeOne Medicines (ONC) has reported Change in Receivables for 10 consecutive years, with $75.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Receivables rose 136.3% year-over-year to $75.3 million; the TTM figure through Mar 2026 stood at $208.4 million (down 25.92% YoY), while the FY2025 annual figure was $165.0 million, down 49.93% from the prior year.
• Change in Receivables climbed to $75.3 million in Q1 2026 per ONC's latest filing, from -$2.3 million in the prior quarter.
• Across five years, Change in Receivables topped out at $136.5 million in Q1 2023 and bottomed at -$292.6 million in Q1 2022.
• Historically, Change in Receivables has averaged $26.7 million across 5 years, with a median of $31.9 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Receivables plunged 1336.7% — and 2024, when it jumped 2156.77%.
• BeOne Medicines' Change in Receivables stood at -$19.4 million in 2022, then jumped by 330.96% to $44.8 million in 2023, then jumped by 180.61% to $125.7 million in 2024, then slumped by 101.86% to -$2.3 million in 2025, then jumped by 3317.95% to $75.3 million in 2026.
• Business Quant data shows ONC's Change in Receivables at $75.3 million in Q1 2026, -$2.3 million in Q4 2025, and $93.9 million in Q3 2025.